Zevra Therapeutics Q4 2025 net revenue rose 31% to USD 34.1 million

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

ZVRA

0.00

Zevra reported Q4 net revenue of USD 34.1 million, up 31% sequentially, including USD 26.4 million from MIPLYFFA net revenue. For FY 2025, net revenue was USD 106.47 million, including USD 87.4 million from MIPLYFFA net revenue. FY 2025 net income was USD 83.23 million, or EPS of USD 1.40 basic and USD 1.35 diluted. Q4 net income was USD 12.2 million, or EPS of USD 0.20 basic and USD 0.19 diluted. Cash, cash equivalents and securities totaled USD 238.9 million at Dec. 31, 2025, and CEO Neil McFarlane said MIPLYFFA’s accelerating performance supports confidence in its long-term potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091605PRIMZONEFULLFEED9668589) on March 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.